Synergist effects of n-acetylcysteine and deferoxamine treatment on behavioral and oxidative parameters induced by chronic mild stress in rats

Neurochemistry International

Volumn 61, Issue 7, 2012, Pages 1072-1080

  Arent, Camila O ^a   Réus, Gislaine Z ^a   Abelaira, Helena M ^a   Ribeiro, Karine F ^a   Steckert, Amanda V ^a   Mina, Francielle ^a   Dal Pizzol, Felipe ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Anhedonia; Deferoxamine; Depression; n Acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; CATALASE; DEFEROXAMINE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AMYGDALOID NUCLEUS; ANHEDONIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; ENZYME ACTIVITY; FOOD INTAKE; HIPPOCAMPUS; MALE; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ACETYLCYSTEINE; ANIMALS; BEHAVIOR, ANIMAL; DEFEROXAMINE; DRUG SYNERGISM; OXIDATIVE STRESS; RATS; STRESS, PSYCHOLOGICAL; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

RATTUS;

EID: 84870051816     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.07.024     Document Type: Article

References (69)

1. B.A. Abdel-Wahab, and R.H. Salama Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice Pharmacol Biochem Behav. 100 2011 59 65
2. H. Aebi Catalase in vitro Methods Enzymol. 105 1984 121 126
3. A.S. Aguiar Jr.; T. Tuon, F.S. Soares, L.G. da Rocha, P.C. Silveira, and R.A. Pinho The effect of n-acetylcysteine and deferoxamine on exercise-induced oxidative damage in striatum and hippocampus of mice Neurochem. Res. 33 2008 729 736
4. J.V. Bannister, and L. Calabrese Assays for superoxide dismutase Methods Biochem. Anal. 32 1987 279 312
5. P.R. Barbosa, M.R. Cardoso, J.F. Daufenbach, C.L. Gonçalves, R.A. Machado, C.A. Roza, G. Scaini, G.T. Rezin, P.F. Schuck, F. Dal-Pizzol, and E.L. Streck Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by n-acetylcysteine and deferoxamine Metab. Brain Dis. 25 2010 219 225
6. M. Berk, D.L. Copolov, O. Dean, K. Lu, S. Jeavons, I. Schapkaitz, M. Anderson-Hunt, and A.I. Bush N-Acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial Biol. Psychiatry 64 2008 468 475
7. M. Berk, O. Dean, S.M. Cotton, C.S. Gama, F. Kapczinski, B.S. Fernandes, K. Kohlmann, S. Jeavons, K. Hewitt, C. Allwang, H. Cobb, A.I. Bush, I. Schapkaitz, S. Dodd, and G.S. Malhi The efficacy of n-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial J. Affect. Disord. 135 2011 389 394
8. A. Boveris, N. Oshino, and B. Chance The cellular production of hydrogen peroxide Biochem. J 8 1972 617 627
9. A. Boveris Determination of the production of superoxide radicals and hydrogen peroxide in mitochondria Methods Enzymol. 105 1984 429 435
10. D. Butterfield, A. Castegna, C. Pocernich, J. Drake, G. Scapagnini, and V. Calabrese Nutritional approaches to combat oxidative stress in Alzheimer's disease J. Nutr. Biochem. 13 2001 444
11. M. Blici, H. Efe, M.A. Koroglu, H.A. Uydu, M. Bekaroglu, and O. Deger Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments J. Affect. Disord. 64 2001 43 51
12. V. Calabrese, G. Scapagnini, S. Latteri, C. Colombrita, A. Ravagna, C. Catalano, G. Pennisi, M. Calvani, and D.A. Butterfield Long-term ethanol administration enhances age-dependent modulation of redox state in different brain regions in the rat: protection by acetyl carnitine Int. J. Tissue React. 24 2002 97 104
13. G. Chen, J. Shi, Z. Hu, and C. Hang Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of n-acetylcysteine Mediators Inflamm. 2008 2008 716458
14. T.M. Dawson, V.L. Dawson, and S.H. Snyder Molecular mechanisms of nitric oxide actions in the brain Ann. N. Y. Acad. Sci. 738 1994 76 85
15. O. Dean, F. Giorlando, and M. Berk N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action J. Psychiatry Neurosci. 36 2011 78 86
16. S. De Flora, A. Izzotti, F. D'Agostin, and C.F. Cesarone Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer Am. J. Med. 91 1991 122 130
17. L.F. de Souza, C. Ritter, G.D. Pens, M. Andrades, E.A. Bernard, J.C. Moreira, and F. Dal-Pizzol Mitochondrial superoxide production is related to the control of cytokine release from peritoneal macrophage after antioxidant treatment in septic rats J. Surg. Res. 141 2007 252 256
18. N. Dimopoulos, C. Piperi, V. Psarra, R.W. Lea, and A. Kalofoutis Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression Psychiatry Res. 161 2008 59 66
19. H.H. Draper, and M.M. Hadley Malondialdehyde determination as index of lipid peroxidation Methods Enzymol. 186 1990 421 431
20. I. Eren, M. Naziroglu, and A. Demirdas Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain Neurochem. Res. 32 2007 1188 1195
21. F.R. Ferreira, C. Biojone, S.R. Joça, and F.S. Guimarães Antidepressant-like effects of N-acetyl-l-cysteine in rats Behav. Pharmacol. 19 2008 747 750
22. M.J. Forlenza, and G.E. Miller Increased serum levels of 8-hydroxy- 20-deoxyguanosine in clinical depression Psychosom. Med. 68 2006 1 7
23. J.J. Fortunato, G.Z. Réus, R.T.R. Kirsch, R.B. Stringari, G.R. Fries, F. Kapczinski, J.E. Hallak, A.W. Zuardi, J.A. Crippa, and J. Quevedo Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties Brain Res. Bull. 81 2010 491 496
24. B.N. Frey, A.C. Andreazza, K.M.M. Ceresér, M.R. Martins, S.S. Valvassori, G.Z. Réus, J. Quevedo, and F. Kapczinski Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania Life Sci. 79 2006 281 286
25. I. Fridovich Superoxide dismutases: regularities and irregularities Harvey Lect. 79 1983 51 75
26. P. Gałecki, J. Szemraj, M. Bienkiewicz, K. Zboralski, and E. Gałecka Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients Hum. Psychopharmacol. 24 2009 277 286
27. P. Gałecki, J. Szemraj, M. Bienkiewicz, A. Florkowski, and E. Gałecka Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment Pharmacol. Rep. 61 2009 436 447
28. G.D. Gamaro, L.P. Manoli, I.L. Torres, R. Silveira, and C. Dalmaz Effects stress on feeding behavior and on monoamine levels in structures Neurochem. Int. 42 2003 107 114
29. L.S.B. Garcia, C.M. Comim, S.S. Valvassori, G.Z. Réus, L. Stertz, F. Kapczinski, E.C. Gavioli, and J. Quevedo Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2009 450 455
30. J.W. Gawryluk, J.F. Wang, A.C. Andreazza, L. Shao, L.N. Yatham, and L.T. Young Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia Int. J. Neuropsychopharmacol. 14 2011 1069 1074
31. F. Giacco, and M. Brownlee Oxidative stress and diabetic complications Circ. Res. 107 2010 1058 1070
32. J.M. Gutteridge, and B. Halliwell Free radicals and antioxidants in the year 2000. A historical look to the future Ann. N. Y. Acad. Sci. 899 2000 136 147
33. B. Halliwell Oxidants and human disease: some new concepts FASEB J. 1 1987 358 364
34. B. Halliwell Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol. Med. 7 1989 645 651
35. I. Hovattaa, J. Juhila, and J. Donnera Oxidative stress in anxiety and comorbid disorders Neurosci. Res. 68 2010 261 275
36. V. Katalinic, D. Modun, I. Music, and M. Boban Gender differences in antioxidant capacity of rat tissues determined by 2, 2′-azinobis (3-ethylbenzothiazoline 6-sulfonate; ABTS) and ferric reducing antioxidant power (FRAP) assays Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 140 2005 47 52
37. R.J. Katz, K.A. Roth, and B.J. Carroll Animal models and human depressive disorders Neurosci. Biobehav. Rev. 5 1981 231 246
38. T.A. Kosten, M.P. Galloway, R.S. Duman, D.S. Russell, and C. D'Sa Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures Neuropsychopharmacol. 33 2008 1545 1558
39. M. Khan, B. Sekhon, M. Jatana, S. Giri, A.G. Gilg, C. Sekhon, I. Singh, and A.K. Singh Administration of n-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke J. Neurosci. Res. 76 2004 519 527
40. D.L. Lafleur, C. Pittenger, B. Kelmendi, T. Gardner, S. Wasylink, R.T. Malison, G. Sanacora, J.H. Krystal, and V. Coric N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder Psychopharmacology (Berlin) 184 2006 254 256
41. R.L. Levine, J.A. Williams, E.R. Stadtman, and E. Shacter Carbonyl assays for determination of oxidatively modified proteins Methods Enzymol. 233 1994 346 357
42. C.H. Lee, J.H. Park, K.Y. Yoo, J.H. Choi, I.K. Hwang, P.D. Ryu, D.H. Kim, Y.G. Kwon, Y.M. Kim, and M.H. Won Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress Exp. Neurol. 229 2011 450 459
43. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the folin phenol reagent J. Biol. Chem. 193 1951 265 267
44. G. Lucca, C.M. Comim, S.S. Valvassori, G.Z. Réus, F. Vuolo, F. Petronilho, E.C. Gavioli, F. Dal-Pizzol, and J. Quevedo Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm J. Psychiatr. Res. 43 2009 864 869
45. G. Lucca, C.M. Comim, S.S. Valvassori, G.Z. Réus, F. Vuolo, F. Petronilho, F. Dal-Pizzol, E.C. Gavioli, and J. Quevedo Effects of chronic mild stress on the oxidative parameters in the rat brain Neurochem. Int. 54 2009 358 362
46. M. Maes, A. Christophe, J. Delanghe, C. Altamura, H. Neels, and H.Y. Meltzer Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients Psychiatry Res. 85 1999 275 291
47. M. Maes, R. Yirmyia, J. Noraberg, S. Brene, J. Hibbeln, G. Perini, M. Kubera, P. Bob, B. Lerer, and M. Maj The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression Metab. Brain Dis. 24 2009 27 53
48. M. Maes, I. Mihaylova, M. Kubera, M. Uytterhoeven, N. Vrydags, and E. Bosmans Increased plasma peroxides and serumoxidized lowdensity lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease J. Affect. Disord. 125 2010 287 294
49. M. Maes, P. Galecki, Y.S. Chang, and M. Berk A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 676 692
50. M. Maes, I. Mihaylova, M. Kubera, J.C. Leunis, and M. Geffard IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology J. Affect. Disord. 135 2011 414 418
51. Maes, M.; Fišar, Z.; Medina, M.; Scapagnini, G.; Nowak, G.; Berk, M.; 2012. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates - Nrf2 activators and GSK-3 inhibitors. Inflammopharmacol. in press.
52. P.V. Magalhães, O.M. Dean, A.I. Bush, D.L. Copolov, G.S. Malhi, K. Kohlmann, S. Jeavons, I. Schapkaitz, M. Anderson-Hunt, and M. Berk N-acetylcysteine for major depressive episodes in bipolar disorder Rev. Bras. Psiquiatr. 33 2011 374 378
53. G.S. Malhi, and M. Berk Does dopamine dysfunction drive depression? Acta Psychiatr. Scand. Suppl. 433 2007 116 124
54. T.M. Michel, S. Camara, T. Tatschner, S. Frangou, A.J. Sheldrick, P. Riederer, and E. Grunblatt Increased xanthine oxidase in the thalamus and putamen in depression World J. Biol. Psychiatry 12 2008 1 7
55. H. Mitani, Y. Shirayama, T. Yamada, K. Maeda, C.R. Ashby Jr, and R. Kawahara Correlation between plasma levels of glutamate, alanine and serine with severity of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 1155 1158
56. M.E. Ozcan, M. Gulec, E. Ozerol, R. Polat, and O. Akyol Antioxidant enzyme activities and oxidative stress in affective disorders Int. Clin. Psychopharmacol. 19 2004 89 95
57. G. Paxinos, and C. Watson The rat brain: stereotaxic coordinates Second ed 1986 Academic Press Australia
58. G.Z. Réus, R.B. Stringari, T.R. Kirsch, G.R. Fries, F. Kapczinski, R. Roesler, and J. Quevedo Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res. Bull. 81 2010 585 589
59. G.Z. Réus, R.B. Stringari, B. de Souza, F. Petronilho, F. Dal-Pizzol, J.E. Hallak, A.W. Zuardi, J.A. Crippa, and J. Quevedo Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus Oxid. Medic. Cell Longev. 5 2010 325 331
60. G.Z. Réus, R.B. Stringari, K.F. Ribeiro, A.K. Ferraro, M.F. Vitto, P. Cesconnetto, C.T. Souza, and J. Quevedo Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain Behav. Brain Res. 221 2011 166 171
61. G.Z. Réus, H.M. Abelaira, R.B. Stringari, G.R. Fries, F. Kapczinski, and J. Quevedo Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats Metab. Brain Dis. 2012 10.1007/s11011-012-9281-2
62. G.T. Rezin, C.L. Gonçalves, J.F. Daufenbach, D.B. Fraga, P.M. Santos, G.K. Ferreira, F.V. Hermani, C.M. Comim, J. Quevedo, and E.L. Streck Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress Brain Res. Bull. 79 2009 418 421
63. E. Sahin, and S. Gumuslu Alterations in brain antioxidant status, protein oxidation and lipid peroxidation in response to different stress models Behav. Brain Res. 155 2004 241 248
64. M. Talarowska, P. Gałecki, M. Maes, A. Gardner, M. Chamielec, A. Orzechowska, K. Bobińska, and E. Kowalczyk Malondialdehyde plasma concentration correlates with declarative and working memory in patients with recurrent depressive disorder Mol. Biol. Rep. 39 2011 5359 5366
65. J.R. Teyssier, S. Ragot, J.C. Cauvet-Gélinier, B. Trojak, and B. Bonin Expression of oxidative stress-response genes is not activated in the prefrontal cortex of patients with depressive disorder Psychiatry Res. 186 2010 244 247
66. M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser Free radicals and antioxidants in normal physiological functions and human disease Int. J. Biochem. Cell Biol. 39 2007 44 84
67. S.S. Valvassori, F.C. Petronilho, G.Z. Réus, A.V. Steckert, V.B. Oliveira, C.R. Boeck, F. Kapczinski, F. Dal-Pizzol, and J. Quevedo Effect of n-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1064 1068
68. H. Yu, and Z.Y. Chen The role of BDNF in depression on the basis of its location in the neural circuity Acta Pharmacol. Sin. 32 2011 3 11
69. A. Zafir, A. Ara, and N. Banu In vivo antioxidant status: a putative target of antidepressant action Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 220 228